Spinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platform Lead candidates ATR 1072 ...

In recent years, mRNA in lipid nanoparticles (mRNA–LNPs) has emerged as a promising strategy for treating numerous conditions ...

Four months after Avidity’s $11.4 billion buyout, Atrium debuted with $270 million in cash and plans to pick up its ...

Through this expansion, Movistar Centre is intended to serve as a year-round showcase for the technological ecosystem associated with Mobile World Congress. The initiative forms part of Telefónica’s ...

Researchers showed that LGP2 binds viral RNA ends and recruits MDA5 molecules to form filament clusters that activate ...

Published as an arXiv preprint, the paper details how unsupervised and self-supervised AI models are matching or surpassing supervised systems while uncovering biological patterns that traditional ...

How innovative technologies like AI and gene editing are advancing rare disease drug discovery and development.

Reflecting on the strength of the community and engagement, Dr. Chaubey said, “Symposium 2026 is a living example of turning possibility into reality – a community united by the desire to be among the ...

Alpha-1 Antitrypsin Deficiency (AATD) is a rare genetic disorder caused by SERPINA1 gene mutations, leading to conditions like pulmonary emphysema and liver dysfunction. The AATD market is in its ...